The setup heading into Rocket Lab's November 9 report is mixed-to-bearish on price action, but fundamentally compelling: revenue growth is running near 66% year-over-year, analyst conviction is high, and the stock has already been punished hard—down nearly 27% from its October peak—which could limit the downside if the quarter delivers.
The Setup: A Steep Descent Before a Catalyst
RKLB closed at $52.37 on November 4, off 3.78% on the session and sitting deep inside a confirmed descending channel pattern. The 100-day trend is a strong downtrend—the stock has shed 52% over that window—and the 5-day and 20-day trends are both pointing lower as well, with the 20-day showing a -23.4% move. The stock is trading below both its 20-day SMA ($56.75) and its 50-day SMA ($63.25), and the RSI sits at a washed-out 38.9—approaching, but not yet at, oversold territory.
The October peak was $71.65 (reached on October 8). The subsequent sell-off found a floor at $49.25 on October 20, and the stock has been choppy since, trading in a rough $50–$59 band. The fact that it bounced off that $49 zone and has held above it—even through several volatile sessions—is the one technical positive. But make no mistake: going into earnings, momentum is clearly negative.
The October plunge was partly sector-driven. The broader space-stock complex sold off sharply, and headlines noted SpaceX's continuing dominance as a competitive overhang. That said, Rocket Lab is approaching its 100th cumulative launch, a milestone that speaks to genuine operational maturation.
What the Options Market Says
Dealer positioning tells a clear story about where the market expects the stock to gravitate post-earnings. The call wall sits at the $60 strike with open interest of 211,634 contracts, and the put wall anchors at $50 with an even larger 330,495 contracts—making the downside magnet the dominant force in the options structure right now.
The options-implied corridor for the post-earnings reaction spans roughly $50 to $60, per gamma positioning. With RKLB currently at $52.37, that corridor puts the stock closer to the floor than the ceiling—a configuration that reflects the market's uncertainty but also suggests dealers are well-hedged against a sharp drop below $50.
Pre-earnings open interest builds show significant put accumulation at the $60 and $65 strikes (OI changes of +20,781 and +16,636 respectively), which is unusual given those strikes are above the current price—suggesting some traders are rolling down hedges or positioning for a failed recovery rally. On the call side, the largest OI builds are clustered at the far-out-of-the-money $85, $90, and $115 strikes, indicating speculative long-shots rather than near-term conviction buying. The overall options signal scores a 47/100, classified as neutral-to-bearish.
The options flow score of 72/100 with a "mixed" flow signal is worth noting: the MACD on the flow model is flashing bullish even as the broader flow leans cautious. This divergence—bullish flow MACD against a bearish price trend—is the key tension heading into the print.
Fundamentals & Estimates
Wall Street expects Rocket Lab to report Q3 2026 revenue of approximately $257 million (consensus average: $257.2M, range: $252M–$265.6M), which would represent a staggering 65.8% year-over-year increase from $155.1M in the year-ago period. That's the number that matters most—Rocket Lab is a growth story, and the market will be watching whether that revenue trajectory is accelerating, holding, or softening.
On the bottom line, analysts expect a loss of $0.07 per share (consensus: –$0.0665, range: –$0.08 to –$0.051). That compares to a loss of –$0.03 in Q3 2025, meaning losses are widening on a per-share basis as the company invests aggressively in Neutron rocket development and manufacturing scale-up.
For the full year 2026, the consensus sits at –$0.27 EPS on ~$959 million in revenue—a 59% revenue jump from 2025's $601.8M. Looking to 2027, analysts see revenue climbing another 39% to $1.33 billion, with losses narrowing substantially toward breakeven.
Estimate revision momentum is a red flag: over the past 30 days, analysts have made 10 downward EPS revisions against just 1 upward revision, for a net revision score of –9. The current-year EPS estimate has drifted from –$0.245 ninety days ago to –$0.275 today. That's not a collapse in expectations, but it signals analysts are quietly nudging their models lower—possibly in anticipation of ongoing Neutron development spending. Any guidance that shows costs accelerating beyond expectations could trigger another round of cuts.
Despite the losses, analyst sentiment remains strongly bullish: 13 Buy ratings, 5 Strong Buy, and 4 Hold—with zero Sell or Strong Sell ratings. The mean price target of $102.15 implies 95% upside from current levels, with KeyBanc reiterating a $100 target and Overweight rating as recently as November 2. The market cap stands at $34.8 billion, with a forward P/E of 833x reflecting the pre-profitability stage—valuation here is entirely a growth-multiple story.
Key Levels to Watch
| Level | Price | Significance |
|---|---|---|
| Call Wall / Resistance | $60.00 | 211,634 contracts OI; 20-day resistance; reclaiming this would be bullish |
| 100-Day Resistance | $61.81 | Overhead ceiling from the 100-day trendline |
| Current Price | $52.37 | Closing price as of Nov 4; inside descending channel |
| 20-Day Support | $50.41 | Near-term floor; must hold to avoid renewed breakdown |
| Put Wall / Floor | $50.00 | 330,495 contracts OI; heavy dealer hedging here acts as a cushion |
| 100-Day Support | $49.52 | Last line of technical defense; a close below this would be bearish confirmation |
| October Low | $49.25 | Swing low; a retest that holds would reinforce base-building |
If RKLB beats on revenue and raises forward guidance, the first meaningful target is a reclaim of $60—which is both the call wall and the 20-day resistance. A sustained move through $61–$62 would shift the technical picture from bearish to neutral. On the downside, if the report disappoints or guidance softens, a test of $50–$49.25 becomes the base case; a close below $49.52 would likely open a move toward the mid-$40s.
Bottom Line
RKLB enters earnings beaten-down and technically weak, but the fundamental growth story—~66% revenue growth expected this quarter, unanimous bullish analyst ratings, and a street target of $102—remains intact. The stock's proximity to the $50 put wall provides a degree of natural support, while the $60 call wall marks the first real hurdle for bulls to clear. For investors, the cleaner approach is to wait for the post-earnings reaction: if RKLB holds above $50 on any weakness and begins to reclaim the $56–$60 zone in the sessions following the report, that would represent a technically improving setup within an unambiguously strong multi-year growth narrative. A clean break above $60 with volume would be the signal to add conviction.
The investment score of 68.1/100 (Hold) reflects exactly this tension—strong fundamental trajectory, poor near-term technicals. The report on November 9 is likely to resolve that tension in one direction. Watch the revenue number and the Neutron development timeline commentary most closely; those are the variables Wall Street will re-price around.
This article was generated by Tradestie Alpha Assistant using live market data (investment scores, options positioning, trendlines, and fundamentals) and reviewed before publication. It is for informational purposes only and is not financial advice. Do your own research before making investment decisions.